您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > SC 79
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
SC 79
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
SC 79图片
CAS NO:305834-79-1
规格:98%
分子量:364.78
包装与价格:
包装价格(元)
10mg电议
50mg电议

产品介绍
Akt activator
CAS:305834-79-1
分子式:C17H17ClN2O5
分子量:364.78
纯度:98%
存储:Store at -20°C

Background:

IC50: N/A


SC 79 is an activator of Akt. Akt/PKB with anti-apoptotic activity (a serine/threonine protein kinase) is one of the major downstream targets of PtdIns P3 signaling pathway.


In vitro: SC79 was identified by a cell-based high-throughput chemical genetic screening, and inhibits Akt membrane translocation. However, Akt was paradoxically activated by SC79in the cytosol, specifically binding to the PH domain of Akt. The conformation of SC79-bound Akt is favorable for phosphorylation by upstream protein kinases. In a mouse model and a hippocampal neuronal culture system for ischemic stroke, the result of augmented neuronal survival is attained, based on the cytosolic activation of Akt by SC79, which is sufficient to recapitulate the primary cellular function of Akt signaling. Thus, SC79, a unique specific Akt activator, may be applied to enhance Akt activity in various physiological and pathological conditions.


In vivo: In aqueous environment, SC79 is relatively unstable. Intriguingly, however, the sustained level of phosphorylated Akt was observed both in cell culture and in vivo after the removal of SC79, indicating that SC79 may act irreversibly. The chemical moieties of SC79 (i.e., nitrile group) could be modified and/or reacts with amino acids. Nevertheless, SC79, a relatively safe drug, was revealed by following fact. Assignment of SC79 treatment much high dose (0.4 mg/g of body weight) did not accelerate any detectable changes in body weight (survival rate, appearance, and behavior) in mice. Achievement of neuronal protective effect by i.p. injection suggests that SC79 also has a good penetration of blood–brain barrier. SC79 can be applied as a chemical platform to develop novel drugs for neurological and other complications


Clinical trial: So far, no clinical study has been conducted.


Reference:
[1] Jo H, Mondal S, Tan D, Nagata E, Takizawa S, Sharma AK, Hou Q, Shanmugasundaram K, Prasad A, Tung JK, Tejeda AO, Man H, Rigby AC, Luo HR.  Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death. Proc Natl Acad Sci U S A. 2012 Jun 26; 109 (26):10581-6.